-
Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
Friday, February 26, 2021 - 7:41am | 445Read More...Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies. The CST study was supposed to be conducted with BeiGene Ltd (...
-
Exclusive: Sinovac IR Director Explains Massive Revenue Opportunity
Friday, June 13, 2014 - 10:46am | 459Read More...In an exclusive interview with Benzinga, director of Investor Relations, Helen Yang, discussed Sinovac’s (NASDAQ: SVA) future opportunities. Sinovac is Chinese biopharmaceutical company which produces, among others, a hepatitis A and B vaccine and is currently preparing to commercialize...
